1. HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
   Andreia Gameiro et al, 2021, Cancers CrossRef
2. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
   Yuesheng Zhang, 2021, Pharmacology & Therapeutics CrossRef
3. Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
   Ezgi Tulukcuoglu Guneri et al, 2022, Cancers CrossRef
4. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody–cytotoxic drug conjugate
   Yoriko Yamashita-Kashima et al, 2019, Cancer Chemotherapy and Pharmacology CrossRef
5. Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
   Yan-cui Liu et al, 2019, Medicine CrossRef
6. Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer
   M. Loi et al, 2022, Clinical and Translational Oncology CrossRef
7. Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
   Yi Xiao et al, 2022, Frontiers in Immunology CrossRef
8. Marginal Corneal Infiltration Following Treatment for Metastatic Breast Cancer with Triple Chemotherapy of Trastuzumab, Pertuzumab & Docetaxel
   Ghyath Kafa et al, 2023, Ocular Immunology and Inflammation CrossRef
9. Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
   Laurence Gauzy-Lazo et al, 2020, SLAS Discovery CrossRef
10. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents
    Ian S. Miller et al, 2019, Scientific Reports CrossRef
11. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
    Mengjun Shu et al, 2020, Scientific Reports CrossRef
12. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes
    Vic Hart et al, 2020, Oncotarget CrossRef
13. Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma
    Andreia Gameiro et al, 2021, Veterinary Sciences CrossRef
14. The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
    Babak Nami et al, 2019, Cancers CrossRef
15. Phage Display Technology and the Development of Phage-Based Vaccines
    Joe A. Fralick et al, 2021, Bacteriophages CrossRef
16. Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells
    María Luisa Sánchez-León et al, 2023, International Journal of Molecular Sciences CrossRef
17. A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response
    Marcella Cardoso et al, 2018, International Journal of Molecular Sciences CrossRef
18. Phage Display Technology and the Development of Phage-Based Vaccines
    Joe A. Fralick et al, 2020, Bacteriophages CrossRef
19. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
    Yoriko Yamashita-Kashima et al, 2020, Cancer Chemotherapy and Pharmacology CrossRef
20. Conventional Chemotherapy Versus Targeted Therapy
    Iago Dillion Lima Cavalcanti et al, 2021, Advances in Cancer Treatment CrossRef
21. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models
    Tina Fonnes et al, 2020, Cancers CrossRef
22. Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
    Hiroki Irie et al, 2020, Cancer Science CrossRef